Equity Brief: Ratings Changes for November 19th: PENN, PETM, PNNT, RMBS, SAP, SDT, SEP, SIRO, SU

Loading...
Loading...

A number of stocks were upgraded and downgraded by equities research analysts today, as reported by Analyst Ratings Network (http://bit.ly/equitybriefdaily) and Equity Brief:

Susquehanna raised its price target on shares of Penn National Gaming PENN from $49.00 to $57.00. They have a positive rating on the stock.

Barclays Capital upgraded shares of Petsmart Inc PETM from an equal weight rating to an overweight rating.

Robert W. Baird downgraded shares of PennantPark Investment Corp. PNNT from an outperform rating to a neutral rating. Their analysts now have a $11.00 price target on the stock, down previously from $12.00.

JPMorgan Chase upgraded shares of Rambus Inc. RMBS from a neutral rating to an overweight rating. JPMorgan Chase now has a $7.00 price target on the stock. They wrote, "After falling 46% year-to-date (S&P 500 up 8.1%), we think the stock, trading at trough-level multiples, is now largely de-risked. At $4.00-$4.50 we think investors are limited from further downside by the value of SBG contracted revenue (even withoutrenewals) plus cash on hand, and the break-up value of the LED and CRI new businesses. We believe a potential settlement with Hynix presents near-term upside for short-term investors."

William Blair upgraded shares of SAP Aktiengesellschaft SAP from a market perform rating to an outperform rating.

Raymond James upgraded shares of SandRidge Mississippian Trust I (SDT) from an underperform rating to a market perform rating.

Citigroup upgraded shares of Spectra Energy Partners, LP (SEP) from a neutral rating to a buy rating. Citigroup now has a $33.00 price target on the stock.

Stifel Nicolaus raised its price target on shares of Sirona Dental (SIRO) from $68.00 to $72.00. They have a buy rating on the stock.

JPMorgan Chase upgraded shares of Suncor Energy Inc. (SU) from a neutral rating to an overweight rating.

Aegis initiated coverage on shares of Trius Therapeutics Inc (TSRX). They issued a buy rating on the stock and set a $15.00 price target.

Stay on top of analysts' coverage with Analyst Ratings Network's free daily email newsletter that provides a concise list of analysts' upgrades, downgrades and initiations. Register at http://bit.ly/equitybriefdaily

Content and Media Contact: newseditor@equitybrief.net





This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Equity Brief via Thomson Reuters ONE

HUG#1659155
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...